(Washington, D.C.) Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Talecris Biotherapeutics Holdings Corp. (”Talecris” or the “Company”) (Nasdaq:TLCR) arising from the Company’s announcement of its intent to be acquired by Grifols, S.A. (”Grifols”). Under the terms of the agreement, Talecris shareholders will receive $19.00 in cash and 0.641 Grifols non-voting (Class B) ordinary shares for every share of Talecris stock they own. Based upon the closing prices of Talecris and Grifols on the trading day prior to the transaction’s announcement, the deal represents a value for the Company’s common stock of $26.16 per share, with a total transaction value of approximately $3.4 billion.

The investigation is focused on the potential unfairness of the consideration to Talecris’ shareholders and the process by which Talecris’ Board of Directors considered and approved the transaction. According to Yahoo! Finance, at least one analyst has set a target price of $28.00 per share for the Company’s stock.

If you are interested in discussing your rights as a Talecris shareholder, or have information relating to this investigation, please contact Finkelstein Thompson’s Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.